Insomnia Market Forecast 2022-2027 | Industry Size, Share & Growth
The latest research study “Insomnia Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” by IMARC Group, finds that the global insomnia market size reached US$ US$ 4.87 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 5.93 Billion by 2027 exhibiting a CAGR of 3.22% during 2022-2027.
Covid-19 Impact:
For More Details-https://www.imarcgroup.com/insomnia-market
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Industry Definition and Application:
Insomnia refers to a sleep disorder that can lower energy levels and affect the mood, health, work performance, and overall life quality of an individual. Its causes include stress, long travels, hectic work schedules, poor sleep habits, binge eating, etc., and excessive consumption of nicotine, caffeine, alcohol, etc.
Insomnia can also be associated with mental health disorders, including post-traumatic stress and the use of drugs, such as antidepressants for asthma or blood pressure and over-the-counter (OTC) for pain relief, allergies, cold, etc. Its treatment options, including cognitive-behavioral therapy (CBT), over-the-counter (OTC) sleep aids, and prescription medications, such as Eszopiclone and Ramelteon, are currently available across various countries.
Request For Sample Report: https://www.imarcgroup.com/insomnia-market/requestsample
Insomnia Market Trends And Drivers:
The increasing prevalence of social isolation, work challenges, and family obligations, owing to the sudden outbreak of the COVID-19 pandemic, is among the key factors stimulating the insomnia market. Apart from this, the rising incidences of stressful events that impact the sleep patterns of individuals are also propelling the market growth.
Besides this, the inflating cases of medical conditions, such as chronic pain, cancer, diabetes, heart disease, asthma, gastroesophageal reflux disease (GERD), overactive thyroid, Parkinson’s disease, and Alzheimer’s disease, are further fueling the global market.
Additionally, hormonal shifts during the menstrual cycle and menopause can lead to the risk of developing insomnia, which is also driving the market growth. Moreover, the elevating investments in testing new treatments, interventions, and tests to prevent, detect, treat, and manage insomnia are expected to positively influence the insomnia market over the forecasted period.
Key highlights of the Report:
-
Market Performance (2016-2021)
-
Market Outlook (2022-2027)
-
COVID-19 Impact on the Market
-
Porter’s Five Forces Analysis
-
Historical, Current and Future Market Trends
-
Market Drivers and Success Factors
-
SWOT Analysis
-
Structure of the Market
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
Report Segmentation:
The report has been segmented the market into following categories:
Breakup by Therapy Type:
Non-Pharmacological Therapy
o Hypnotherapy
o Cognitive Behavioral Therapy
o Medical Devices
o Others
Pharmacological Therapy
o Prescription Sleep Aids
o Over-The-Counter Sleep Aids
Breakup by Drug Class:
o Antidepressants
o Melatonin Antagonist
o Benzodiazepines
o Nonbenzodiazepines
o Orexin Antagonist
o Others
Breakup by Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Drug Stores
o Online Pharmacies
By Geography:
North America
o United States
o Canada
· Asia-Pacific
o China
o Japan
o India
o South Korea
o Australia
o Indonesia
o Others
· Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Russia
o Others
· Latin America
o Brazil
o Mexico
o Others
· Middle East and Africa
List of Major Key Players:
The major players in the market are Astellas Pharma Inc., Aurobindo Pharma Limited, Biocodex, Eisai Co. Ltd., Mallinckrodt Pharmaceuticals, Merck & Co. Inc., Neurim Pharmaceuticals Inc., Pfizer Inc., Sanofi S.A., Sumitomo Dainippon Pharma Co. Ltd. (Sumitomo Chemical Co. Ltd.), Takeda Pharmaceutical Company Limited and Vanda Pharmaceuticals Inc.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
0
